- Home
- IBO vs NRXS Comparison
IBO vs NRXS Comparison
Compare IBO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- NRXS
- Stock Information
- Founded
- IBO 2018
- NRXS 2011
- Country
- IBO United States
- NRXS United States
- Employees
- IBO N/A
- NRXS N/A
- Industry
- IBO
- NRXS
- Sector
- IBO
- NRXS
- Exchange
- IBO NYSE
- NRXS Nasdaq
- Market Cap
- IBO 17.9M
- NRXS 17.3M
- IPO Year
- IBO 2024
- NRXS 2023
- Fundamental
- Price
- IBO $1.56
- NRXS $2.85
- Analyst Decision
- IBO
- NRXS
- Analyst Count
- IBO 0
- NRXS 0
- Target Price
- IBO N/A
- NRXS N/A
- AVG Volume (30 Days)
- IBO 31.8K
- NRXS 30.7K
- Earning Date
- IBO 02-23-2025
- NRXS 11-12-2024
- Dividend Yield
- IBO N/A
- NRXS N/A
- EPS Growth
- IBO N/A
- NRXS N/A
- EPS
- IBO 0.01
- NRXS N/A
- Revenue
- IBO N/A
- NRXS $2,456,219.00
- Revenue This Year
- IBO N/A
- NRXS $383.16
- Revenue Next Year
- IBO N/A
- NRXS N/A
- P/E Ratio
- IBO $129.11
- NRXS N/A
- Revenue Growth
- IBO N/A
- NRXS N/A
- 52 Week Low
- IBO $1.16
- NRXS $2.00
- 52 Week High
- IBO $3.25
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- NRXS 61.76
- Support Level
- IBO N/A
- NRXS $2.48
- Resistance Level
- IBO N/A
- NRXS $2.83
- Average True Range (ATR)
- IBO 0.00
- NRXS 0.26
- MACD
- IBO 0.00
- NRXS 0.05
- Stochastic Oscillator
- IBO 0.00
- NRXS 72.86
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).